Univariate Poisson regression model for new-onset CV-AEs after starting TKI therapy
| . | CV-AEs: No . | CV-AEs: Yes . | IRR (95% CI) . | P* . |
|---|---|---|---|---|
| Continuous variables, mean (SD) | ||||
| Age, y | 45 (14) | 53 (15) | 1.04 (1.03-1.05) | <.001 |
| Serum albumin, g/dL | 4.3 (1) | 4 (1) | 0.48 (0.36-0.64) | <.001 |
| BMI, kg/m2 | 28 (7) | 30 (8) | 1.04 (1.03-1.06) | <.001 |
| Categorical variables, n (%) | ||||
| BMI ≥ 30, kg/m2 | ||||
| No | 217 (74) | 142 (60) | ||
| Yes | 77 (26) | 95 (40) | 1.76 (1.36-2.28) | <.001 |
| TKI type | ||||
| IM400 | 36 (12) | 35 (15) | ||
| IM800 | 113 (38) | 90 (38) | 0.77 (0.52-1.13) | .184 |
| Nilotinib | 64 (22) | 44 (19) | 1.00 (0.64-1.56) | .996 |
| Dasatinib | 65 (22) | 41 (17) | 0.86 (0.55-1.36) | .527 |
| Ponatinib | 16 (5) | 27 (11) | 4.50 (2.72-7.44) | <.001 |
| Prior hypertension | ||||
| No | 160 (54) | 101 (43) | ||
| Yes | 134 (45) | 136 (57) | 1.75 (1.35-2.26) | <.001 |
| Prior diabetes | ||||
| No | 257 (87) | 196 (83) | ||
| Yes | 37 (13) | 41 (17) | 1.58 (1.13-2.21) | .008 |
| Prior stroke | ||||
| No | 292 (99) | 232 (98) | ||
| Yes | 2 (0.68) | 5 (2) | 3.30 (1.36-8.00) | .008 |
| Prior CAD | ||||
| No | 279 (95) | 208 (87) | ||
| Yes | 15 (5) | 29 (12) | 2.03 (1.37-2.99) | <.001 |
| Prior arrhythmia | ||||
| No | 286 (97) | 227 (96) | ||
| Yes | 8 (2) | 10 (4) | 1.94 (1.03-3.65) | .041 |
| Prior PVD | ||||
| No | 292 (99) | 233 (98) | ||
| Yes | 2 (1) | 4 (2) | 2.75 (1.02-7.38) | .045 |
| Risk factors | ||||
| 0 | 76 (26) | 34 (14) | ||
| 1 | 102 (35) | 71 (30) | 1.70 (1.13-2.56) | .011 |
| 2 | 78 (26) | 82 (35) | 2.31 (1.55-3.44) | <.001 |
| ≥3 | 38 (13) | 50 (21) | 3.08 (1.99-4.77) | <.001 |
| . | CV-AEs: No . | CV-AEs: Yes . | IRR (95% CI) . | P* . |
|---|---|---|---|---|
| Continuous variables, mean (SD) | ||||
| Age, y | 45 (14) | 53 (15) | 1.04 (1.03-1.05) | <.001 |
| Serum albumin, g/dL | 4.3 (1) | 4 (1) | 0.48 (0.36-0.64) | <.001 |
| BMI, kg/m2 | 28 (7) | 30 (8) | 1.04 (1.03-1.06) | <.001 |
| Categorical variables, n (%) | ||||
| BMI ≥ 30, kg/m2 | ||||
| No | 217 (74) | 142 (60) | ||
| Yes | 77 (26) | 95 (40) | 1.76 (1.36-2.28) | <.001 |
| TKI type | ||||
| IM400 | 36 (12) | 35 (15) | ||
| IM800 | 113 (38) | 90 (38) | 0.77 (0.52-1.13) | .184 |
| Nilotinib | 64 (22) | 44 (19) | 1.00 (0.64-1.56) | .996 |
| Dasatinib | 65 (22) | 41 (17) | 0.86 (0.55-1.36) | .527 |
| Ponatinib | 16 (5) | 27 (11) | 4.50 (2.72-7.44) | <.001 |
| Prior hypertension | ||||
| No | 160 (54) | 101 (43) | ||
| Yes | 134 (45) | 136 (57) | 1.75 (1.35-2.26) | <.001 |
| Prior diabetes | ||||
| No | 257 (87) | 196 (83) | ||
| Yes | 37 (13) | 41 (17) | 1.58 (1.13-2.21) | .008 |
| Prior stroke | ||||
| No | 292 (99) | 232 (98) | ||
| Yes | 2 (0.68) | 5 (2) | 3.30 (1.36-8.00) | .008 |
| Prior CAD | ||||
| No | 279 (95) | 208 (87) | ||
| Yes | 15 (5) | 29 (12) | 2.03 (1.37-2.99) | <.001 |
| Prior arrhythmia | ||||
| No | 286 (97) | 227 (96) | ||
| Yes | 8 (2) | 10 (4) | 1.94 (1.03-3.65) | .041 |
| Prior PVD | ||||
| No | 292 (99) | 233 (98) | ||
| Yes | 2 (1) | 4 (2) | 2.75 (1.02-7.38) | .045 |
| Risk factors | ||||
| 0 | 76 (26) | 34 (14) | ||
| 1 | 102 (35) | 71 (30) | 1.70 (1.13-2.56) | .011 |
| 2 | 78 (26) | 82 (35) | 2.31 (1.55-3.44) | <.001 |
| ≥3 | 38 (13) | 50 (21) | 3.08 (1.99-4.77) | <.001 |
Analysis showing univariate Poisson regression models for new-onset vascular AEs (CV-AEs) after starting TKI therapy.
SD, standard deviation.
Bold indicates significant P values (P < .05).